Exenatide

Summary

Exenatide is a synthetic exendin-4 analog and the first GLP-1 receptor agonist approved for type 2 diabetes mellitus. Available as twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations. It improves glycemic control, promotes weight loss, and has a low intrinsic risk of hypoglycemia as a monotherapy.

Mechanism of Action

Mimics incretin hormone GLP-1; binds and activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central mechanisms.

Routes of Administration

Goals & Uses

• Blood pressure reductionCardiovascularModerate
• Cardiovascular risk reductionCardiovascularModerate
• Beta-cell function preservationMetabolicLow
• Weight reductionMetabolicHigh
• Glycemic control in type 2 diabetesMetabolicHigh

Contraindications

• Personal or family history of medullary thyroid carcinomaOncologicHigh
• Type 1 diabetes mellitus or diabetic ketoacidosisMetabolicHigh
• Severe renal impairment (eGFR <30 mL/min/1.73m²)RenalHigh
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Genetic/EndocrineHigh
• History of hypersensitivity to exenatideImmunologicalHigh

Adverse Effects

• HypoglycemiaMetabolicCommonAbnormally low blood glucose
• Injection site reactionsLocalCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• Acute pancreatitisGastrointestinalRare
• DiarrheaGastrointestinalCommonLoose or frequent stools

Drug Interactions

• Antibiotics (time-sensitive oral agents)Low
• Oral contraceptivesLowDelayed gastric emptying may affect absorption timing
• InsulinModerateMay increase risk of low blood sugar
• WarfarinModerate
• SulfonylureasModerateMay increase risk of low blood sugar

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Elderly patients (≥75 years)AgeRelative
• Moderate renal impairment (eGFR 30–50 mL/min/1.73m²)RenalRelative
• History of pancreatitisGastrointestinalRelative

Regulatory Status

• European UnionApprovedApproved: Treatment of type 2 diabetes mellitus in adults in combination with other glucose-lowering medicines or as monotherapy when metformin is inappropriateByetta approved by EMA in 2006; Bydureon approved 2011. Subject to routine pharmacovigilance.
• United StatesApprovedApproved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusByetta approved 2005; Bydureon approved 2012; Bydureon BCise autoinjector approved 2017. Black box warning for thyroid C-cell tumors.
• United KingdomApprovedApproved: Type 2 diabetes mellitus as adjunct to diet, exercise, and other antidiabetic agentsApproved via legacy EMA process; MHRA oversight post-Brexit. NICE guidance supports use in specific patient subgroups meeting BMI/HbA1c criteria.

FDA approved Byetta (exenatide injection) in April 2005 for type 2 diabetes. Bydureon (exenatide extended-release) approved January 2012. Bydureon BCise (autoinjector) approved October 2017. Not approved for type 1 diabetes or as a weight-loss agent per se. Black box warning for risk of thyroid C-cell tumors in rodents (class effect).

Evidence & Sources

No sources recorded yet.